Company intelligence / Profile preview

Leonard-Meron Biosciences, Inc.

Cranford, New Jersey, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Mino-Lok demonstrated safety in its Phase 2b trial conducted at the MD Anderson Cancer Center in Houston and was entering Phase 3 trials. The FDA granted a Qualified Infectious Disease Product (QIDP) designation for Mino-Lok, making it eligible for Fast Track designation, Priority Review, and a five-year extension of market exclusivity.

Therapeutic areas: Infectious Diseases
Modalities: Antibiotic lock solution
Industry: Biotech

Drug pipeline

1 asset

minocycline + edetate + ethyl alcohol

Phase 3

Indications: Catheter-related bloodstream infections

Beyond the preview

Go deeper on Leonard-Meron Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leonard-Meron Biosciences, Inc..

Explore the full profile